World journal of clinical oncology最新文献

{"title":"Homeobox C6 plays an oncogenic role in bladder cancer.","authors":"Ding-Jin Lu, Hai-Rong Wang, You-Sheng Xu, Hai-Bo Huang, Qi-Gang Zhong, Yuan-Ning Luo, Jian-Feng Qi, Hong-Chao Wu, Jin-Ye Pei, Kun Zhang, Chao-Xiong Xu, Tian-Xian Wang, Wei Zhang, Yu-Hong Zhou, Zhi-Guang Huang, Fu-Bo Wang","doi":"10.5306/wjco.v16.i5.103830","DOIUrl":"10.5306/wjco.v16.i5.103830","url":null,"abstract":"<p><strong>Background: </strong>Bladder cancer (BLCA) is a common urological tumor. Homeobox C6 (<i>HOXC6</i>) is an HOX family gene that has an oncogenic effect in various malignancies.</p><p><strong>Aim: </strong>To investigate the expression and function of <i>HOXC6</i> in BLCA.</p><p><strong>Methods: </strong>This study employed immunohistochemistry, along with global chip and sequencing data for BLCA, to comprehensively evaluate the protein and mRNA expression of <i>HOXC6</i> in BLCA. RNA interference technology was employed to knock down the mRNA expression of <i>HOXC6</i> in BLCA cells, and the impact of reduced <i>HOXC6</i> expression on cellular function was assessed. Additionally, we explored the potential mechanisms of <i>HOXC6</i> in BLCA by aggregating <i>HOXC6</i> chromatin immunoprecipitation sequencing data.</p><p><strong>Results: </strong>The immunohistochemistry results, sequencing data, and microarray data revealed that both the mRNA and protein expressions of <i>HOXC6</i> in BLCA were notably greater than the expressions in non-cancerous tissues. Knocking down the expression of <i>HOXC6</i> considerably limited the function of cell proliferation, migration, and invasion abilities of BLCA cells, elevated cell apoptosis, and triggered the G0/G1 phase blockade. The potential target genes of <i>HOXC6</i> were enriched in pathways such as chemical carcinogenesis and reactive oxygen species. A notable positive correlation between <i>HOXC6</i> mRNA expression and its target gene timeless circadian regulator (<i>TIMELESS</i>) was revealed. Notable binding peak signals for <i>HOXC6</i> were identified in the promoter region of <i>TIMELESS</i>.</p><p><strong>Conclusion: </strong><i>HOXC6</i> is upregulated in BLCA and may influence the cellular functions of BLCA by regulating the expression of the target gene <i>TIMELESS</i>.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 5","pages":"103830"},"PeriodicalIF":2.6,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149837/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of the family and socioeconomic factors as a tool of prevention of breast cancer.","authors":"Riya Karmakar, Yaswanth Nagisetti, Arvind Mukundan, Hsiang-Chen Wang","doi":"10.5306/wjco.v16.i5.106569","DOIUrl":"10.5306/wjco.v16.i5.106569","url":null,"abstract":"<p><p>The manuscript by Agidew <i>et al</i>, evaluates the critical role of family background and socioeconomic status in shaping breast cancer awareness, attitudes, and preventive behaviors, particularly in low-resource settings. Breast cancer continues to be a leading cause of cancer-related deaths globally, with a disproportionate impact on women in low- and middle-income countries. Recent research by Agidew <i>et al</i> underscores a significant association between family history of breast cancer and elevated levels of knowledge, positive attitudes, and proactive behaviors among women in Northeast Ethiopia. Building upon these findings, this editorial explores the psychological mechanisms and behavioral tendencies that drive greater awareness among women with familial exposure to the disease. Additionally, it highlights persistent socioeconomic challenges-such as limited healthcare access, education disparities, and cultural stigmas-that impede widespread preventive action, especially among women without a known family history. The editorial emphasizes the necessity of integrated public health strategies that combine culturally sensitive education, community outreach, and accessible screening services. Drawing from clinical and policy perspectives, it offers guidance on how to strengthen early detection and preventive care in under-resourced environments. Ultimately, the piece advocates for a more inclusive approach to breast cancer education and prevention that addresses both familial influence and systemic socioeconomic barriers.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 5","pages":"106569"},"PeriodicalIF":2.6,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Last decade of advances in gastric neuroendocrine tumors: Innovations, challenges, and future directions.","authors":"Grigorios Christodoulidis, Marina Nektaria Kouliou, Dimitrios Ragias, Dimitrios Chatziisaak, Eirini Sara Agko, Dimitrios Schizas, Dimitrios Zacharoulis","doi":"10.5306/wjco.v16.i5.104577","DOIUrl":"10.5306/wjco.v16.i5.104577","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Gastric neuroendocrine tumors (G-NETs) are rare tumors originating from enterochromaffin-like cells, with an incidence of 0.4 per 100000 annually. There are three main types: (1) Type I, linked to chronic atrophic gastritis and hypergastrinemia, makes up 75%-80% of G-NETs; (2) Type II, associated with Zollinger-Ellison syndrome (ZES) and multiple endocrine neoplasia, comprises 5%; and (3) Type III, sporadic tumors with a higher metastatic potential, accounting for 15%-25%. Diagnosis involves endoscopy, biopsy, and histological examination. Additional methods include serum gastrin testing, immunohistochemistry, and imaging techniques such as computer tomography or magnetic resonance imaging for detecting metastasis. Type I treatment usually involves endoscopic resection (ER), with surgical resection for recurrence. Somatostatin analogs (SSAs) can reduce tumor size, and the prognosis is generally excellent. Type II treatment centers on surgical removal of the gastrinoma, with ER for smaller lesions and SSAs for symptom management. Type III requires surgical resection (partial or total gastrectomy) with lymph node dissection, and possibly chemotherapy. This type has a worse prognosis due to its aggressive nature. Emerging treatments like Peptide Receptor Radionuclide Therapy are promising for advanced cases, and ongoing research into immunotherapies is expanding future treatment options. Regular endoscopic follow-up is crucial to monitor for recurrence or metastasis across all types. Our literature review explores the current perspectives on G-NETs and highlights the importance of further research to improve diagnostic precision and treatment, particularly for those associated with less favorable cases.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Aim: &lt;/strong&gt;To improve diagnostic precision and treatment, particularly for those associated with less favorable cases.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A systematic search was conducted in PubMed, Scopus, and Web of Science until September 2024. Two independent reviewers screened titles, abstracts, and full texts for eligibility based on G-NET treatment in adults. Eligible studies included cohort studies, clinical trials, case series, and case reports, while &lt;i&gt;in vitro&lt;/i&gt;, pediatric, and non-English studies were excluded. Relevant data were extracted independently, and disagreements were resolved through discussion. Study quality was assessed using appropriate tools.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;G-NETs are rare, classified into three types: (1) Type I; (2) Type II; and (3) Type III. Type I G-NETs, often associated with chronic atrophic gastritis, are typically slow-growing and low-grade, with favorable outcomes following surgical resection. Type II G-NETs arise in hypergastrinemia conditions like multiple endocrine neoplasia and ZES, showing moderate malignancy risk. Type III G-NETs, the most aggressive and least common, present with distant metastases and poor prognosis. Diagnosis relies on endosc","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 5","pages":"104577"},"PeriodicalIF":2.6,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preservation of the nipple-areolar complex during subcutaneous mastectomy: A surgical and diagnostic method.","authors":"Anna S Sukhotko, Anna Bumbu, Serghei Covantsev","doi":"10.5306/wjco.v16.i5.104398","DOIUrl":"10.5306/wjco.v16.i5.104398","url":null,"abstract":"<p><p>Simultaneous oncological and reconstructive plastic surgery on the mammary gland in the treatment of cancer is currently one of the important stages in the psychological rehabilitation of patients. In order to achieve a good cosmetic result, reconstruction must be performed simultaneously with radical surgical treatment. Currently, there are a large number of methods for performing breast reconstruction. One of the most commonly used is radical subcutaneous/skin-sparing mastectomy with simultaneous reconstruction with a silicone endoprosthesis. Grand W Carlson type technique is used, with skin incisions in the form of an inverted T is usually performed in patients with large mammary gland with severe grade III ptosis, as the patients usually require reduction of excess skin. However, the most vulnerable aspects of this type of reconstruction is the impossibility of preserving the nipple-areolar complex (NAC), which is associated with a high risk of developing such complications as partial/complete necrosis of the NAC. The current study provides an overview of an original method to decrease the risk of necrosis of NAC with evaluation of blood supply of the nipple and inferior deepithelialized flap using real-time intraoperative Doppler ultrasonography and indocyanine green fluorescence system.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 5","pages":"104398"},"PeriodicalIF":2.6,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149833/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum pro-inflammatory cytokines as potential biomarkers for the diagnosis of gastric carcinoma.","authors":"Le Ren, Jun Liu, Ya-Yun Xu, Zhen-Wang Shi","doi":"10.5306/wjco.v16.i5.107551","DOIUrl":"10.5306/wjco.v16.i5.107551","url":null,"abstract":"<p><strong>Background: </strong>Multiple lines of evidence have indicated that pro-inflammatory cytokines play a role in the pathophysiology of gastric carcinoma (GC).</p><p><strong>Aim: </strong>To identify potential serum cytokine-based biomarkers for GC diagnosis.</p><p><strong>Methods: </strong>The study cohort comprised 50 patients diagnosed with GC and 50 healthy control subjects. A panel of 7 pro-inflammatory cytokines, including interleukin (IL)-1β, IL-2, IL-6, IL-8, IL-12, tumor necrosis factor-α, and interferon-γ (IFN-γ) were quantified using multiplex Luminex assays. Comparative analyses were conducted to evaluate cytokine levels between the GC patients and healthy controls. The diagnostic potential of serum pro-inflammatory cytokines in differentiating GC patients from healthy individuals was assessed through receiver operating characteristic (ROC) curve analysis. The correlation between serum cytokine levels and disease severity, as classified by the tumor-node-metastasis staging system, was analyzed using Spearman's rank correlation coefficient.</p><p><strong>Results: </strong>In comparison to the control group, patients with GC demonstrated significantly elevated serum levels of IL-1β (<i>t</i> = -4.089, <i>P</i> < 0.001), IL-6 (<i>t</i> = -3.983, <i>P</i> < 0.001), IL-8 (<i>t</i> = -5.460, <i>P</i> < 0.001), and IFN-γ (<i>t</i> = -2.856, <i>P</i> = 0.005). ROC curve analysis indicated that the area under the curve values for IL-1β, IL-6, and IL-8 exceeded 0.7, effectively distinguishing GC patients from healthy controls. Additionally, serum levels of IL-1β (<i>r</i> = 0.424, <i>P</i> = 0.012) and IL-6 (<i>r</i> = 0.742, <i>P</i> < 0.001) were positively correlated with the T stage in GC patients. Similarly, serum concentrations of IL-1β (<i>r</i> = 0.356, <i>P</i> = 0.039) and IL-6 (<i>r</i> = 0.441, <i>P</i> = 0.008) exhibited a positive association with the N stage in these patients.</p><p><strong>Conclusion: </strong>These findings suggest that circulating pro-inflammatory cytokines, such as IL-1β, IL-6, and IL-8, may serve as potential biomarkers for the diagnosis of GC.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 5","pages":"107551"},"PeriodicalIF":2.6,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149838/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnosis and treatment of metachronous multiple primary carcinoma: A case report and review of literature.","authors":"Min Luo, Rui-Na Liu, Zhen-Mei He, Qian-Fu Liang, Feng-Ling Huang","doi":"10.5306/wjco.v16.i5.105444","DOIUrl":"10.5306/wjco.v16.i5.105444","url":null,"abstract":"<p><strong>Background: </strong>Multiple primary carcinoma (MPC) refers to two or more types of primary malignant tumors occurring simultaneously or sequentially in the same patient. Breast cancer is one of the most common malignant tumors affecting women. On the other hand, diffuse large B-cell lymphoma (DLBCL) is the most frequent form of non-Hodgkin's lymphoma (NHL). In clinical practice, the simultaneous existence of metachronous primary breast cancer and lymphoma is rare. In this case, we highlight the significance of multidisciplinary management and advanced imaging techniques in the early identification and treatment of MPC cases.</p><p><strong>Case summary: </strong>In this study, we report a case of a 40-year-old female who was diagnosed with invasive ductal carcinoma of the breast (T3N1M0 stage IIIA LuminalB type) as the first primary cancer and DLBCL (stage IIIA) as the second primary cancer. The patient underwent the modified radical mastectomy for left breast cancer and received Rituximab, cyclophospha-mide, hydroxydaunorubicin, Oncovin (vincristine) and prednisolone regimen chemotherapy treatment for DLBCL. As of now, the patient is in stable condition. The successful diagnosis of the present patient highlights the need for multidisciplinary management and adoption of advanced imaging techniques to identify the second primary cancer, especially NHL.</p><p><strong>Conclusion: </strong>Accurate diagnosis and management of metachronous MPC requires an interdisciplinary team and selection of an appropriate treatment plan.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 5","pages":"105444"},"PeriodicalIF":2.6,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149822/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between skeletal muscle mass and prognosis in patients with liver cancer receiving targeted therapy: A meta-analysis.","authors":"Ling-Hong Wan, Bi-Jing Mao, Bin Wang","doi":"10.5306/wjco.v16.i5.102611","DOIUrl":"10.5306/wjco.v16.i5.102611","url":null,"abstract":"<p><strong>Background: </strong>Many studies have found that sarcopenia is related to the survival of patients with liver cancer, which may lead to worse prognosis.</p><p><strong>Aim: </strong>To investigate the relationship between skeletal muscle mass and prognosis in patients with liver cancer receiving targeted therapy by meta-analysis.</p><p><strong>Methods: </strong>PubMed, Embase, Cochrane Library, and Web of Science were searched for clinical studies on the relationship between skeletal muscle index (SMI) and the prognosis of patients with liver cancer receiving targeted therapy from inception to March 1, 2022. Meta-analysis and sensitivity analysis of the data were performed using Stata 16.0 software.</p><p><strong>Results: </strong>A total of 6877 studies were searched, and finally 12 articles with 1715 cases were included. Meta-analysis result of 8 articles showed that compared with non-low SMI group, the overall survival (OS) of patients with liver cancer in the low SMI group was significantly shorter (hazard ratio = 1.60, 95% confidence interval: 1.44-1.77, <i>P</i> = 0.000). Meta-analysis result of 4 articles showed that, compared with low SMI group, patients in the non-low SMI group had longer OS (hazard ratio = 0.59, 95% confidence interval: 0.38-0.91, <i>P</i> = 0.018).</p><p><strong>Conclusion: </strong>Skeletal muscle mass is positively correlated with OS in patients with liver cancer receiving targeted therapy.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 5","pages":"102611"},"PeriodicalIF":2.6,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Knowledge structure analysis and network visualization of tumor-associated macrophages in hepatocellular carcinoma research: A bibliometric mapping.","authors":"Ping-Li Mo, Ming Lin, Bo-Wen Gao, Shang-Bin Zhang, Jian-Ping Chen","doi":"10.5306/wjco.v16.i5.102747","DOIUrl":"10.5306/wjco.v16.i5.102747","url":null,"abstract":"<p><strong>Background: </strong>Tumor-associated macrophages (TAMs) have demonstrated significant potential as a research and treatment approach for hepatocellular carcinoma (HCC). Nevertheless, a comprehensive quantitative analysis of TAMs in HCC remained insufficient. Therefore, the objective of this study was to employ bibliometric methods to investigate the development trends and research frontiers pertaining to this field.</p><p><strong>Aim: </strong>To determine the knowledge structure and current research hotspots by bibliometric analysis of scholarly papers pertaining to TAMs in HCC.</p><p><strong>Methods: </strong>The present study employed the Web of Science Core Collection to identify all papers related to TAMs in HCC research. Utilizing the Analysis Platform of Bibliometrics, CiteSpace 6.2.R4, and Vosviewer 1.6.19, the study conducted a comprehensive analysis encompassing multiple dimensions such as publication quantity, countries of origin, affiliated institutions, publishing journals, contributing authors, co-references, author keywords, and emerging frontiers within this research domain.</p><p><strong>Results: </strong>A thorough examination was undertaken on 818 papers within this particular field, published between January 1, 1985 to September 1, 2023, which has witnessed a substantial surge in scholarly contributions since 2012, with a notable outbreak in 2019. China was serving as the central hub in this field, with Fudan University leading in terms of publications and citations. Chinese scholars have taken the forefront in driving the research expansion within this field. <i>Hepatology</i> emerged as the most influential journal in this field. The study by Qian and Pollard in 2010 received the highest number of co-citations. It was observed that the citation bursts of references coincided with the outbreak of publications. Notably, \"tumor microenvironment\", \"immunotherapy\", \"prognostic\", \"inflammation\", and \"polarization\", <i>etc.</i> emerged as frequently occurring keywords in this field. Of particular interest, \"immune evasion\", \"immune infiltration\", and \"cancer genome atlas\" were identified as emerging frontiers in recent research.</p><p><strong>Conclusion: </strong>The field of TAMs in HCC exhibited considerable potential, as evidenced by the promising prospects of immunotherapeutic interventions targeting TAMs for the amelioration of HCC. The emerging frontiers in this field primarily revolved around modulating the immunosuppressive characteristics of TAMs within a liver-specific immune environment, with a focus on how to counter immune evasion and reduce immune infiltration.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 5","pages":"102747"},"PeriodicalIF":2.6,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149817/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neuroendocrine neoplasms of the lung: The latest updates.","authors":"Riccardo Orlandi","doi":"10.5306/wjco.v16.i5.106630","DOIUrl":"10.5306/wjco.v16.i5.106630","url":null,"abstract":"<p><p>Neuroendocrine neoplasms are a group of tumors with heterogenous malignancy that evolve from neuroendocrine cells, most frequently in the gastrointestinal tract and in the lung. The latest 2021 World Health Organization (WHO) classification of lung tumors defines neuroendocrine neoplasms of the lung as an independent group of tumors, including typical and atypical neuroendocrine tumors and small cell and large cell neuroendocrine carcinomas. Although the overall nomenclature is essentially unchanged from the fourth WHO classification, there are several clinically relevant updates. In this review article, we discuss the epidemiological, clinical, diagnostic, therapeutic and prognostic features of these fascinating neoplasms, including the latest insights, current challenges and future perspectives.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 5","pages":"106630"},"PeriodicalIF":2.6,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149839/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rituximab-based regimens for primary cardiac lymphoma: A systematic review of outcomes, challenges and future directions.","authors":"Syed Faqeer Hussain Bokhari, Danyal Bakht, Abdul Haseeb Hasan, Muhammad Ali Abid, Maaz Amir, Khawar Ali, Muhammad Arsham Javed, Faria Khilji, Asma Iqbal, Wahidullah Dost","doi":"10.5306/wjco.v16.i5.104471","DOIUrl":"10.5306/wjco.v16.i5.104471","url":null,"abstract":"<p><strong>Background: </strong>Primary cardiac lymphoma (PCL) is a rare subset of cardiac tumors, often diagnosed late due to nonspecific symptoms. It predominantly affects immunocompromised individuals, primarily in the pericardium and right heart. Late diagnosis mimics common cardiac ailments, leading to poor prognosis.</p><p><strong>Aim: </strong>To systematically review the efficacy of rituximab in treating PCL either alone or in various chemotherapeutic regimens. Secondary objectives include evaluating morphological subtypes, assessing treatment regimens, and analyzing outcomes focusing on remission and adverse events.</p><p><strong>Methods: </strong>Following PRISMA guidelines, a comprehensive literature search was conducted across multiple databases, including PubMed, Hinari, Web of Science, and Scopus. English-language studies reporting the use of rituximab in treating PCL in humans were included. Study selection involved initial screening of titles and abstracts followed by full-text examination and data extraction.</p><p><strong>Results: </strong>Thirty-three case reports involving 36 patients were included in this systematic review. Diffuse large B-cell lymphoma was the predominant morphological subtype observed. The rituximab, cyclophosphamide, doxorubicin, oncovin, and prednisolone regimen emerged as the most commonly employed treatment strategy, indicating widespread acceptance and efficacy in PCL management. Combination therapies, including surgical intervention, showed promise in achieving complete remission, while some studies reported mortality despite aggressive treatment approaches.</p><p><strong>Conclusion: </strong>Rituximab, particularly in combination with chemotherapy regimens, represents a significant advancement in PCL management, offering hope for improved patient outcomes. However, challenges such as variable treatment responses and adverse events underscore the complexity of managing PCL. Further research is warranted to refine therapeutic strategies and enhance diagnostic approaches for this rare cardiac malignancy.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 5","pages":"104471"},"PeriodicalIF":2.6,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12149827/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144276137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}